Alpha Cognition announces proposed public offering of shares

VANCOUVER & DALLAS - Alpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, announced Tuesday its proposal to offer common shares and pre-funded warrants in an underwritten public offering.

The company plans to grant the underwriter a 30-day option to purchase additional common shares equal to 15% of the total shares sold in the offering. The proposed offering remains subject to market conditions, with no guarantees regarding its completion, size, or terms.

According to the company’s statement, proceeds from the offering would be directed toward accelerating the commercial launch of its Alzheimer’s treatment ZUNVEYL, with emphasis on sales expansion, marketing, and enhancing payer coverage infrastructure.

Titan Partners Group, a division of American Capital Partners, will serve as the sole bookrunner for the proposed offering.

The offering is being conducted pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on August 22, 2025, and declared effective on August 29, 2025. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.

ZUNVEYL is described in the press release as a patented acetylcholinesterase inhibitor for Alzheimer’s disease treatment with expected minimal gastrointestinal side effects. The drug’s active metabolite binds to neuronal nicotinic receptors, particularly the alpha-7 subtype, which is associated with positive effects on cognition.

The announcement notes that the offering will be made only through the prospectus supplement and accompanying prospectus forming part of the effective registration statement. With a gross profit margin of 70% in the last twelve months and analysts setting a price target significantly above current levels, investors seeking comprehensive analysis can access the detailed Pro Research Report available exclusively on InvestingPro, which covers all key metrics and growth prospects for ACOG.

In other recent news, Alpha Cognition Inc. reported its Q2 2025 earnings, which revealed a significant operating loss and a net loss of $10.5 million. Despite the commercial launch of its Alzheimer’s treatment, Zunveil, the company faced challenges with high operating expenses. In another development, Alpha Cognition entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC to offer and sell common shares with a potential gross sales value of up to $75 million. This agreement allows the company to sell shares at its discretion through Wainwright, acting as a sales agent. H.C. Wainwright & Co. will receive a commission of up to 3.0% of the gross sales price for the shares sold. Alpha Cognition is not obligated to sell any shares under this agreement and may suspend or terminate the offering at any time. These recent developments provide a glimpse into the company’s current financial strategies and market activities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.